Keyword: Scripps Research Institute
Scott Gottlieb goes back to biotech investing; Seattle Genetics taps first CCO; Affimed parts with CSO; and CSL Behring poaches former Biogen exec.
The week’s biotech news included a surgical gel that prevents tumors from spreading and an antibody against opioids.
Using broadly neutralizing single-domain antibodies from llamas, scientists have designed a vaccine that can potentially combat almost all flu viruses.
Scientists have developed a small molecule that can selectively target RNA and could pave the way for a pill that can treat genetic diseases.
Scripps researchers pinpointed a protein that can sense blood flow and prompt tiny blood vessels to dilate. It may be a target for drug development.
Understanding how some helper T cells become killer T cells could lead to better vaccine design for HIV and hep C.
The National Institutes of Health has tapped Fitbit to provide 10,000 devices for the All of Us research program.
Vividion Therapeutics seeks to deploy its synthetic and proteomic chemistry platforms to “dramatically expand” the number of targets that can be approached therapeutically. Its technology identifies previously unknown druggable targets in the human proteome.
The past week brought new discoveries related to opioid addiction, heart failure and inflammation.
An international group of scientists is turning to a surprising ally in the quest to develop an HIV vaccine: the cow.